<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813928</url>
  </required_header>
  <id_info>
    <org_study_id>I15031</org_study_id>
    <nct_id>NCT02813928</nct_id>
  </id_info>
  <brief_title>Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment</brief_title>
  <acronym>ADNCirc</acronym>
  <official_title>Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inspite of curative treatment 30-50% patients with ColoRectal Cancer (CRC) develop tumor
      relapse during the first 3 years after treatment of the primary tumor. Treatment of relapses
      is based on surgical resection, when possible, chemotherapy and targeted therapies. To detect
      recurrences or metastases, a surveillance strategy is recommended for patients able to
      withstand complementary treatment during a five-year period. Over this period, the
      probability of one false-positive result is 87%. Considering that less than 10% of recurrent
      patients are suitable for potentially curative treatment and that more intensive programs
      enable an increase of the overall rate of curative resection but do not result in reduced
      mortality, less time and cost-consuming, tailored follow-up is necessary. The level of
      circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex®
      method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and
      surveillance.

      Tubes for ccfDNA analysis will be taken during medical examination at the same time of the
      CEA dosage (if it was not made before the consultation). Cryotubes of plasma will be sent for
      analysis in the laboratory INSERM (National Health Institute) of Montpellier and the
      remaining plasma will be kept in biological collection.

      Patients will have a consultation of follow-up every 3-4 months during which the dosage of
      CEA and ccfDNA will be realized as well as a medical examination, a general examination
      (weight, size, and blood pressure), an evaluation of the indices of performance status and a
      nutritional evaluation in case of loss of weight.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of recurrences detected for patients curatively treated for a CRC stages II and III within the 3 years of follow-up.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">473</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ccfDNA analysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ccfDNA analysis</intervention_name>
    <description>The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance</description>
    <arm_group_label>ccfDNA analysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Primary diagnosis of stages II and III CRC:

          -  is already operated and histological proven (biopsy at least)

          -  is patient that must be operated: curative treatment for stages II and III CRC

          -  Patient benefiting from a program personalized by care

          -  Written informed consent

        Exclusion Criteria:

          -  Patient already treated for stages II and III CRC and in surveillance

          -  Patient with indication or with palliative treatment

          -  Pregnant or nursing patients

          -  Known pregnancy

          -  Difficulties to understand the protocol

          -  Patients under protection measure (guardianship, curatorship, protection of justice)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aurillac Hospital</name>
      <address>
        <city>Aurillac</city>
        <zip>15000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bergonie institute</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Cèdres clinical</name>
      <address>
        <city>Brive-la-Gaillarde</city>
        <zip>19000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brive Hospital</name>
      <address>
        <city>Brive</city>
        <zip>19000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cahors Hospital</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gueret Hospital</name>
      <address>
        <city>Guéret</city>
        <zip>23000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La marche clinical</name>
      <address>
        <city>Guéret</city>
        <zip>23000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limoges Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87 042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier Institute</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moulins Hospital</name>
      <address>
        <city>Moulins</city>
        <zip>03000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Antoine AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perigueux clinical</name>
      <address>
        <city>Périgueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Périgueux Hospital</name>
      <address>
        <city>Périgueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Junien Hospital</name>
      <address>
        <city>Saint-Junien</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte feyre Hospital</name>
      <address>
        <city>Sainte feyre</city>
        <zip>23000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vichy Hospital</name>
      <address>
        <city>Vichy</city>
        <zip>03200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ColoRectal Cancer</keyword>
  <keyword>Cancerology</keyword>
  <keyword>Translational Research</keyword>
  <keyword>ccfDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>the data are anonymized</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

